



EU Big Data Stakeholder Forum 2024

28 November 2024

Presented by Carla Torre, HMA-EMA Big Data Steering Group member

An agency of the European Union





1 13 November 2024
2 EMA/51063/2024

3 Regulatory Science Research Needs
4 2024 update - DRAFT

Start of public consultation	13 November 2024
End of public consultation	18 December 2024
Please provide comments using this template . The completed comments form should be sent to regulators.science@ema.europa.eu .	
To comment on a specific RSRN and priority topic in the table at chapter 2, please refer to the respective RSRN ID (e.g. CT1_1; CT1_2...)	

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

- **Easy platform to exchange information/experiences/opinions (e.g. patients groups);**
 - SM may hold potentially valuable **safety information** in several contexts (e.g. detecting undisclosed signals, capturing less frequently reported AE, or detect AE earlier than traditional methods). WEB-RADR IMI project, etc.
 - SM could also detect the **potential for abuse or misuse of certain medications, off-label**, evaluate **acceptability and risk perception by patients** (...).
- **The use of SM data in medicines evaluation is not standard practice yet in EU medicines regulation and remains very limited.**
 - The **validity of information** posted requires careful analysis and interpretation (unstructured text, images or videos); **selection bias/representativeness** (DUS)
 - **Volume and complexity of the data:** the development and standardization of more effective and robust mining and processing methods is necessary and is yet to be established.

Need for focused initiatives / proof of concept studies to assess SM's utility across various regulatory applications (e.g. safety/misuse)

- **Important source of patient health generated data:** capture data that is not available on healthcare databases (claims, emHR, registries, etc.)
- Potential **advantages of mobile endpoints** : real-time data capture and analytics, less frequent visits (in trials), ability to capture day-to-day variability by collecting data continuously, complement PRO/CRO, more likely to reflect habitual/daily experiences, etc.
- **The role of digital, specifically mobile devices in drug development and regulation, is only expected to grow (product related submissions, interactions with the regulators have been identified regarding discussion on mHealth tools or data) – but not without challenges.**
- (unknown) **validity** of information and interpretation | substantial **variability** in terms of reporting **completeness, terminology, variability, interoperability** | choice of **relevant and fit-for-purpose digital endpoints**

1) technical expertise requirements/capacity building (building on use cases examples /learnings on the use of mHealth data in EU Medicine Regulation); 2) early dialogue with regulators/qualification procedures (e.g. SAWP) and 3) roadmap/guidance is needed.

- The **Pharmacogenomics and the Real-World Data Specialised Interest Areas (SIA)** of the **Methodology ESEC** are now established and will help to share learnings and build knowledge amongst regulators. **Efforts should continue in that direction.**
- **DARWIN EU studies** are being run, this should continue in the future, **by expanding the network's access to more genomic data.** **Learnings** should be shared for continuous improvements and acceptance of generated data to support regulatory decision-making.
- **European Health Data Space (EHDS)** will help to access and share more and more data. The EHDS should be leveraged to harness the increasing amount of **pharmacogenomic information** and **integrate** it with other sources of data, such as electronic health records.

